Literature DB >> 31205201

Subclinical atherosclerosis due to increase of plasma aldosterone concentrations in essential hypertensive individuals.

Antonio Concistrè, Luigi Petramala, Valeria Bisogni, Martina Mezzadri, Federica Olmati, Vincenza Saracino, Gaia Oliviero, Maria Bonvicini, Gianfranco Tonnarini, Gino Iannucci, Claudio Letizia.   

Abstract

BACKGROUND AND AIMS: The adrenal mineralocorticoid system plays a key role in cardiovascular, metabolic and renal damage. This study aimed to assess the relationship between plasma aldosterone concentration (PAC) and some surrogate markers of subclinical atherosclerosis, such as carotid intima-media thickness (cIMT), ankle-brachial index (ABI) and biochemical parameters in patients with essential hypertension. METHODS AND
RESULTS: From January 2014 to December 2017, we consecutively enrolled 804 essential hypertensive patients (407 men and 397 women, mean age 50 ± 14 years) without cardiovascular complications, distinguishing patients in quartiles according to PAC. Compared with the first quartile, the highest PAC quartile was associated with the highest levels of serum uric acid (SUA) (5.3 ± 1.3 vs. 5.0 ± 1.0 mg/dl; P = 0.01), triglycerides (117.5 ± 15.7 vs. 106.8 ± 10.5 mg/dl; P < 0.05), 24-h urinary albumin excretion (UAE) (38.8 ±  vs. 7.6 ± mg/24 h; P < 0.05), cIMT (0.87 ± 0.22 vs. 0.80 ± 0.21 mm; P = 0.001) and increased prevalence of carotid plaques (26 vs. 16%; P < 0.005). Moreover, we found that in patients with PAC more than 150 pg/ml, the ABI was significantly lower than those with PAC < 150 pg/ml (1.01 ± 0.09 vs. 1.10 ± 0.09; P < 0.022). PAC was also found to be an independent predictor of the presence of carotid plaques and pathological ABI (<0.9) in essential hypertensive individuals.
CONCLUSION: Our results revealed that higher PAC values are strongly associated with some metabolic variables, as triglycerides, UAE, cIMT, worse ABI and major prevalence of carotid plaques that, together with elevated blood pressure values, are strictly correlated with higher risk of atherosclerosis and cardiovascular complications.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31205201     DOI: 10.1097/HJH.0000000000002170

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  4 in total

1.  Vasculometabolic and Inflammatory Effects of Aldosterone in Obesity.

Authors:  Charlotte D C C van der Heijden; Rob Ter Horst; Inge C L van den Munckhof; Kiki Schraa; Jacqueline de Graaf; Leo A B Joosten; A H Jan Danser; Mihai G Netea; Jaap Deinum; Joost Rutten; Niels P Riksen
Journal:  J Clin Endocrinol Metab       Date:  2020-08-01       Impact factor: 5.958

2.  The Prevalence, Distribution, and Extent of Subclinical Atherosclerosis and Its Relation With Serum Uric Acid in Hypertension Population.

Authors:  Fei Liu; Simei Hui; Tesfaldet H Hidru; Yinong Jiang; Ying Zhang; Yan Lu; Haichen Lv; Sharen Lee; Yunlong Xia; Xiaolei Yang
Journal:  Front Cardiovasc Med       Date:  2021-04-15

3.  Altered Tregs Differentiation and Impaired Autophagy Correlate to Atherosclerotic Disease.

Authors:  Sara Mandatori; Ilenia Pacella; Vincenzo Marzolla; Caterina Mammi; Donatella Starace; Fabrizio Padula; Laura Vitiello; Andrea Armani; Carmine Savoia; Maurizio Taurino; Daniela De Zio; Claudia Giampietri; Silvia Piconese; Francesco Cecconi; Massimiliano Caprio; Antonio Filippini
Journal:  Front Immunol       Date:  2020-03-13       Impact factor: 7.561

4.  Associations Between Metabolic Profiles and Target-Organ Damage in Chinese Individuals With Primary Aldosteronism.

Authors:  Shao-Ling Zhang; Jing-Wei Gao; Ying Guo; Qi-Ling Feng; Ju-Ying Tang; Li Yan; Jing-Feng Wang; Hua Cheng; Pin-Ming Liu
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-25       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.